Biogen Idec Inc.'s confirmation of months-long buzz that the company is talking with potential buyers boosted the stock and started onlookers speculating about advantages, drawbacks and hurdles - as well as the timing of a potential deal, given worries that still linger over Tysabri, and given Biogen's possibly value-stimulating pipeline news in the year ahead. (BioWorld Today)